Rivulet Media (RIVU) 10-Q 11 Aug 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - Jun. 30, 2015 - shares	Total
Document And Entity Information
Entity Registrant Name	Bio-Matrix Scientific Group, Inc.
Entity Central Index Key	1,079,282
Document Type	10-Q
Document Period End Date	Jun. 30, 2015
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding	4,232,931,245
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2,015

Consolidated Balance Sheet (Una

Consolidated Balance Sheet (Unaudited) - USD ($)	Jun. 30, 2015	Sep. 30, 2014
CURRENT ASSETS
Cash	$ 230,904	$ 502
Prepaid Expenses	21,289	15,000
Note Receivable	12,051	10,422
Interest Receivable	1,081	233
Total Current Assets	265,325	26,157
OTHER ASSETS
Deposits	4,200	4,200
Available for Sale Securities	3,000	3,000
Total Other Assets	7,200	7,200
TOTAL ASSETS	272,525	33,357
CURRENT LIABILITIES
Accounts Payable	143,663	158,492
Notes Payable	251,836	379,233
Bank Overdraft	0	6,137
Accrued Payroll	682,595	587,094
Accrued Payroll Taxes	49,237	51,117
Accrued Interest	313,678	$ 271,495
Accrued Rent	5,000
Accrued Expenses	5,000	$ 5,000
Convertible Note Payable Net of Unamortized Discount	158,120	97,701
Due to Affiliate	0	0
Due to Subsidiary Shareholder	0	0
Current portion, note payable to affiliated party	1,000	1,000
Total Current Liabilities	1,610,129	1,557,269
Total Liabilities	1,610,129	1,557,269
STOCKHOLDERS EQUITY (DEFICIT)
Preferred Stock ($0.0001 par value) 20,000,000 shares authorized; 2,063,821 issued and outstanding as of June 30, 2015 and September 30, 2014	207	207
Series AA Preferred ($0.0001 par value) 100,000 shares authorized; 94,852 issued and outstanding as of June 30, 2015 and September 30, 2014	9	9
Series AAA Preferred ($0.0001 par value) 1,000,000 shares authorized 40,000 shares issued and outstanding as of June 30, 2015 and September 30, 2014	4	4
Series B Preferred Shares ($0.0001 par value) 2,000,000 shares authorized; 725,409 issued and outstanding as of June 30, 2015 and September 30, 2014 respectively	73	73
Common Stock ($0.0001 par value) 5,000,000,000 shares authorized; 4,232,931,345 and 3,079,900,942 issued and outstanding as of June 30, 2015 and September 30, 2014 respectively	423,292	307,989
Non Voting Convertible Preferred Stock ($1 Par value) 200,000 shares authorized; 0 shares issued and outstanding as of June 30, 2015 and September 30, 2014	0	0
Additional Paid in capital	28,451,806	16,510,439
Contributed Capital	509,355	509,355
Retained Earnings (Deficit)	10,395,818	22,461,356
Accumulated Other Comprehensive Income (Loss)	(41,333,361)	(41,333,361)
Total Stockholders' Equity (Deficit) Biomatrix Scientific Group, Inc.	(1,552,797)	(1,543,929)
Noncontrolling Interest in subsidiary	215,193	20,017
Total Stockholders' Equity	(1,337,604)	(1,523,912)
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY (DEFICIT)	$ 272,525	$ 33,357

Consolidated Balance Sheet (Par

Consolidated Balance Sheet (Parenthetical) - $ / shares	Jun. 30, 2015	Sep. 30, 2014
Preferred stock; par value	$ 0.0001	$ 0.0001
Preferred stock; shares authorized	20,000,000	20,000,000
Preferred stock; shares issued	2,063,821	2,063,821
Preferred stock; shares outstanding	2,063,821	2,063,821
Common stock; par value	$ 0.0001	$ 0.0001
Common Stock; shares authorized	5,000,000,000	5,000,000,000
Common stock; shares issued	4,232,931,345	3,079,900,942
Common stock; shares outstanding	4,232,931,345	3,079,900,942
Series AA
Preferred stock; par value	$ 0.0001	$ 0.0001
Preferred stock; shares authorized	100,000	100,000
Preferred stock; shares issued	94,852	94,852
Preferred stock; shares outstanding	94,852	94,852
Series AAA
Preferred stock; par value	$ 0.0001	$ 0.0001
Preferred stock; shares authorized	1,000,000	1,000,000
Preferred stock; shares issued	40,000	40,000
Preferred stock; shares outstanding	40,000	40,000
Series B
Preferred stock; par value	$ 0.0001	$ 0.0001
Preferred stock; shares authorized	2,000,000	2,000,000
Preferred stock; shares issued	725,409	725,409
Preferred stock; shares outstanding	725,409	725,409
Non Voting
Preferred stock; par value	$ 1	$ 1
Preferred stock; shares authorized	200,000	200,000
Preferred stock; shares issued	0	0
Preferred stock; shares outstanding	0	0

Consolidated Statement of Opera

Consolidated Statement of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
REVENUES	$ 0	$ 0	$ 0	$ 0
COST AND EXPENSES
Research and Development	68,081	0	93,287	13,867
General and Administrative	494,963	132,975	989,693	459,411
Consulting and Professional Fees	87,367	39,995	473,562	147,998
Rent	16,200	0	43,071	0
Total Costs and Expenses	666,611	172,970	1,599,614	621,276
OPERATING LOSS	(666,611)	(172,970)	(1,599,614)	(621,276)
OTHER INCOME & (EXPENSES)
Interest Income	297	14	848	14
Interest Expense	(11,726)	$ (8,981)	(44,991)	(26,388)
Loss on Settlement of Debt through Equity Issuance	(140,000)		(976,530)	$ (984,730)
Loss on Settlement of Debt through Issuance of Common Shares of Regen biopharma, Inc. below fair value	(937,425)		(9,116,857)
Interest Expense attributable to amortization of discount	(73,387)		(77,419)
Expense Related to issuance of Convertible Debt to Star City	0		(247,500)
Preferred Shares of Regen Biopharma, Inc. issued pursuant to contractual obligations	$ (321)		$ (3,475)
Other Expenses		$ (65,000)		$ (65,000)
Total Other Income & (Expense)	$ (1,162,562)	(73,477)	$ (10,465,924)	(1,075,614)
NET INCOME (LOSS)	(1,829,173)	(246,447)	(12,065,538)	(1,696,890)
NET INCOME (LOSS) before equity in subsidiary losses	(1,829,173)	(246,447)	(12,065,538)	(1,696,890)
NET INCOME (LOSS)	(1,829,173)	(246,447)	(12,065,538)	(1,696,890)
Less: (Net Income)Loss attributable to noncontrolling interest Regen Biopharma, Inc.	1,274,739	63,388	8,486,861	144,927
NET INCOME (LOSS) available to common shareholders	$ (554,434)	$ (183,059)	$ (3,578,677)	$ (1,551,963)
BASIC AND FULLY DILUTED EARNINGS (LOSS)	$ (0.0001)	$ (0.0001)	$ (0.0009)	$ (0.0006)
Weighted average number of shares outstanding	4,160,041,891	2,951,045,145	3,817,242,852	2,819,220,513

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net Income (loss)	$ (12,065,538)	$ (1,696,890)
Adjustments to reconcile net Income to net cash (used in) provided by operating activities:
Stock issued for services rendered by consultants		$ 3,570
Stock issued for interest
Stock issued for expenses		$ (48,000)
Interest Expense attributable to amortization of discount	$ 77,419
Changes in operating assets and liabilities:
(Increase) Decrease in Prepaid Expenses	(6,289)
Increase (Decrease) in Accounts Payable	(14,830)	$ 5,902
Increase (Decrease) in Accrued Expenses	140,804	$ (37,581)
Increase (Decrease) in bank Overdraft	(6,137)
(Increase) Decrease in Interest Receivable	$ (848)	$ (14)
Increase (Decrease) in Due to Affiliate		(34,895)
(Increase) Decrease in Note Receivable	$ (1,629)	(2,222)
Net Cash Provided by (Used in) Operating Activities	(11,877,048)	(1,713,750)
CASH FLOWS FROM FINANCING ACTIVITIES
Additional paid in Capital	681,274	300,000
Increase (Decrease) in due to subsidiary shareholder	0	100,000
Principal borrowings (repayments) on notes and Convertible Debentures	60,103	$ 246,360
Principal borrowings (repayments) on Convertible Debentures	$ 1,272,686
(Increase) Decrease in Deferred Financing Costs		$ 65,000
Loss on Settlement of Debt through Equity Issuance	$ 10,093,387	984,730
Net Cash Provided by (Used in) Financing Activities	12,107,450	1,696,090
Net Increase (Decrease) in Cash	230,402	(17,660)
Cash at Beginning of Period	502	116,714
Cash at End of Period	230,904	99,054
Supplemental Disclosure of Noncash investing and financing activities:
Common Shares Issued for Debt	157,500	$ 83,000
Common Shares of Regen Biopharma, Inc. Issued for Debt	$ 972,686

Consolidated Statement of Compr

Consolidated Statement of Comprehensive Income (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
Net Income (Loss)	$ (1,829,173)	$ (246,447)	$ (12,065,538)	$ (1,696,890)
Add: Unrealized Gains on Securities	$ 1,000	$ (6,000)	0	0
Less: Unrealized Losses on Securities			0	(2,000)
Total Other Comprehensive Income (Loss)	$ 1,000	$ (6,000)	0	(2,000)
Comprehensive Income	$ (1,828,173)	$ (252,447)	$ (12,065,538)	$ (1,698,890)

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	9 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Summary of Significant Accounting Policies	NOTE 1. ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Bio-Matrix Scientific Group, Inc. (the “Company”) was organized October 6, 1998, under the laws of the State of Delaware as Tasco International, Inc. From October 6, 1998 to June 3, 2006 its activities have been limited to capital formation, organization, and development of its business plan to provide production of visual content and other digital media, including still media, 360-degree images, video, animation and audio for the Internet. On July 3, 2006 the Company abandoned its efforts in the field of digital media production when it acquired 100% of the share capital of Bio-Matrix Scientific Group, Inc., a Nevada corporation, (“BMSG”) for consideration consisting of 10,000,000 shares of the common stock of the Company and the cancellation of 10,000,000 shares of the Company owned and held by John Lauring. As a result of this transaction, the former stockholder of BMSG held approximately 80% of the voting capital stock of the Company immediately after the transaction. For financial accounting purposes, this acquisition was a reverse acquisition of the Company by BMSG under the purchase method of accounting, and was treated as a recapitalization with BMSG as the acquirer. Accordingly, the financial statements have been prepared to give retroactive effect to August 2, 2005 (date of inception), of the reverse acquisition completed on July 3, 2006, and represent the operations of BMSG. Through its controlled subsidiary, Regen BioPharma, Inc., the Company intends to engage primarily in the development of regenerative medical applications which we intend to license from other entities up to the point of successful completion of Phase I and or Phase II clinical trials after which we would either attempt to sell or license those developed applications or, alternatively, advance the application further to Phase III clinical trials The Company holds 18.3% of the equity and 70% of the voting power of Regen BioPharma, Inc. A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end. B. PRINCIPLES OF CONSOLIDATION The consolidated financial statements include the accounts of Bio-Matrix Scientific Group, inc., a Delaware corporation, Bio Matrix Scientific Group, Inc, a Nevada corporation and a wholly owned subsidiary (“BMSG”), Regen BioPharma, Inc., a Nevada corporation and controlled subsidiary (Regen) and Entest BioMedical, Inc., (“Entest’), a Nevada corporation which was a majority owned subsidiary up to February 3, 2011.  Significant inter-company transactions have been eliminated. C. USE OF ESTIMATES The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. All estimates are of a normal, recurring nature and are required for the fair presentation of the financial statements. Actual results could differ from those estimates. D. CASH EQUIVALENTS The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents. E. PROPERTY AND EQUIPMENT Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized. F. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.  A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value: Level 1: Quoted prices in active markets for identical assets or liabilities Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s financial instruments as of June 30, 2015 consisted of Securities Available for Sale consisting of 10,000,000 shares of Entest Biomedical, Inc and a Note Receivable from Entest Biomedical, Inc. for $12,051 . The fair value of Securities Available for sale as of June 30, 2015 were valued according to the Level 1 input. The carrying amount of the financial instruments is equal to the fair value as determined by the Company. The fair value of the Note Receivable was valued according to Level 3 input. G. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of June 30, 2015 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward.  However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19. H. The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. All options and convertible debt outstanding has an anti-dilutive effect on the EPS, therefore Diluted Earnings per Share are the same as basic earnings per share. I. ADVERTISING Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 and $0 for the quarter ended June 30, 2015 and the year ended September 30, 2014 respectively.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Jun. 30, 2015
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	NOTE 2 RECENT ACCOUNTING PRONOUNCEMENTS In June 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-10, which eliminated certain financial reporting requirements of companies previously identified as "Development Stage Entities" (Topic 915). The amendments in this ASU simplify accounting guidance by removing all incremental financial reporting requirements for development stage entities. The amendments also reduce data maintenance and, for those entities subject to audit, audit costs by eliminating the requirement for development stage entities to present inception-to-date information in the statements of income, cash flows, and shareholder equity. Early application of each of the amendments is permitted for any annual reporting period or interim period for which the entity's financial statements have not yet been issued (public business entities) or made available for issuance (other entities). Upon adoption, entities will no longer present or disclose any information required by Topic 915. The Company has adopted this standard. The following accounting standards updates were recently issued and have not yet been adopted by us. These standards are currently under review to determine their impact on our consolidated financial position, results of operations, or cash flows. In May 2014, FASB issued Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers. The revenue recognition standard affects all entities that have contracts with customers, except for certain items. The new revenue recognition standard eliminates the transaction-and industry-specific revenue recognition guidance under current GAAP and replaces it with a principle-based approach for determining revenue recognition. Public entities are required to adopt the revenue recognition standard for reporting periods beginning after December 15, 2016, and interim and annual reporting periods thereafter. Early adoption is not permitted for public entities. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements. In June 2014, FASB issued Accounting Standards Update (ASU) No. 2014-12 Compensation — Stock Compensation (Topic 718), Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period. A performance target in a share-based payment that affects vesting and that could be achieved after the requisite service period should be accounted for as a performance condition under Accounting Standards Codification (ASC) 718, Compensation — Stock Compensation. As a result, the target is not reflected in the estimation of the award's grant date fair value. Compensation cost would be recognized over the required service period, if it is probable that the performance condition will be achieved. The guidance is effective for annual periods beginning after 15 December 2015 and interim periods within those annual periods. Early adoption is permitted. The Company has reviewed the applicable ASU and has not, at the current time, quantified the effects of this pronouncement, however it believes that there will be no material effect on the consolidated financial statements. In August 2014, FASB issued Accounting Standards Update (ASU) No. 2014-15 Preparation of Financial Statements Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern. Under generally accepted accounting principles (GAAP), continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity's liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. If and when an entity's liquidation becomes imminent, financial statements should be prepared under the liquidation basis of accounting in accordance with Subtopic 205-30, Presentation of Financial Statements—Liquidation Basis of Accounting. Even when an entity's liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity's ability to continue as a going concern. In those situations, financial statements should continue to be prepared under the going concern basis of accounting, but the amendments in this Update should be followed to determine whether to disclose information about the relevant conditions and events. The amendments in this Update are effective for the annual period ending after December 15, 2016, and for annual periods and interim periods thereafter. Early application is permitted. The Company will evaluate the going concern considerations in this ASU, however, at the current period, management does not believe that it has met the conditions which would subject these financial statements for additional disclosure. On January 31, 2013, the FASB issued Accounting Standards Update [ASU] 2013-01, entitled Clarifying the Scope of Disclosures about Offsetting Assets and Liabilities. The guidance in ASU 2013-01 amends the requirements in the FASB Accounting Standards Codification [FASB ASC] Topic 210, entitled Balance Sheet. The ASU 2013-01 amendments to FASB ASC 210 clarify that ordinary trade receivables and receivables in general are not within the scope of ASU 2011-11, entitled Disclosure about Offsetting Assets and Liabilities, where that ASU amended the guidance in FASB ASC 210. As those disclosures now are modified with the ASU 2013-01 amendments, the FASB ASC 210 balance sheet offsetting disclosures now clearly are applicable only where reporting entities are involved with bifurcated embedded derivatives, repurchase agreements, reverse repurchase agreements, and securities borrowing and lending transactions that either are offset using the FASB ASC 210 or 815 requirements, or that are subject to enforceable master netting arrangements or similar agreements. ASU 2013-01 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. The adoption of this ASU is not expected to have a material impact on our financial statements. On February 28, 2013, the FASB issued Accounting Standards Update [ASU] 2013-04, entitled Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date. The ASU 2013-04 amendments add to the guidance in FASB Accounting Standards Codification [FASB ASC] Topic 405, entitled Liabilities and require reporting entities to measure obligations resulting from certain joint and several liability arrangements where the total amount of the obligation is fixed as of the reporting date, as the sum of the following: The amount the reporting entity agreed to pay on the basis of its arrangement among co-obligors. Any additional amounts the reporting entity expects to pay on behalf of its co-obligors. While early adoption of the amended guidance is permitted, for public companies, the guidance is required to be implemented in fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments need to be implemented retrospectively to all prior periods presented for obligations resulting from joint and several liability arrangements that exist at the beginning of the year of adoption. The adoption of ASU 2013-04 is not expected to have a material effect on the Company’s operating results or financial position. On April 22, 2013, the FASB issued Accounting Standards Update [ASU] 2013-07, entitled Liquidation Basis of Accounting. With ASU 2013-07, the FASB amends the guidance in the FASB Accounting Standards Codification [FASB ASC] Topic 205, entitled Presentation of Financial Statements. The amendments serve to clarify when and how reporting entities should apply the liquidation basis of accounting. The guidance is applicable to all reporting entities, whether they are public or private companies or not-for-profit entities. The guidance also provides principles for the recognition of assets and liabilities and disclosures, as well as related financial statement presentation requirements. The requirements in ASU 2013-07 are effective for annual reporting periods beginning after December 15, 2013, and interim reporting periods within those annual periods. Reporting entities are required to apply the requirements in ASU 2013-07 prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of ASU 2013-07 is not expected to have a material effect on the Company’s operating results or financial position. A variety of proposed or otherwise potential accounting standards are currently under study by standard setting organizations and various regulatory agencies. Due to the tentative and preliminary nature of those proposed standards, the Company’s management has not determined whether implementation of such standards would be material to its financial statements.

Options and Warrants

Options and Warrants	9 Months Ended
	Jun. 30, 2015
Notes to Financial Statements
Options and Warrants	NOTE 3. OPTIONS AND WARRANTS As of June 30, 2015 the Company has no options or warrants outstanding.

Going Concern

Going Concern	9 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	NOTE 4. GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. Exclusive of a onetime non-cash gain of $41,645,688 recognized upon the deconsolidation of Entest Biomedical, Inc., the Company generated net losses of $30,586,221 excluding $663,649 of Equity in Net Losses of Entest Biomedical, Inc. recognized) during the period from August 2, 2005 (inception) through June 30, 2015. This condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's continuation as a going concern is dependent on its ability to meet its obligations, to obtain additional financing as may be required and ultimately to attain profitability. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. Management plans to raise additional funds by offering securities for cash. During the quarter ended March 31, 2015 Regen Biopharma Inc. raised $775,000 through the issuance of convertible debt. During the quarter ended June 30, 2015 Regen Biopharma Inc. raised $90,000 through the issuance of convertible debt.

Income Taxes

Income Taxes	9 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 5. INCOME TAXES As of June 30, 2015 Deferred tax assets: Net operating tax carry forwards $ 10,412,444 Other -0- Gross deferred tax assets 10,412, 444 Valuation allowance (10,412,444 ) Net deferred tax assets $ -0- As of June 30, 2015 the Company has a Deferred Tax Asset of $10,412,444 completely attributable to net operating loss carry forwards of approximately $30,624,837 ( which expire 20 years from the date the loss was incurred) consisting of (a) $38,616, of Net Operating Loss Carry forwards acquired in the reverse acquisition of BMSG and (b) $30,586,221Â Â Â attributable to Bio-Matrix Scientific Group, Inc. a Delaware corporation, BMSG and Regen. Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry forwards are expected to be available to reduce taxable income. The achievement of required future taxable income is uncertain. In addition, the reverse acquisition of BMSG has resulted in a change of control. Internal Revenue Code Sec 382 limits the amount of income that may be offset by net operating loss (NOL) carryovers after an ownership change. As a result, the Company has the Company recorded a valuation allowance reducing all deferred tax assets to 0. Income tax is calculated at the 34% Federal Corporate Rate.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 6. RELATED PARTY TRANSACTIONS As of June 30, 2015 the Company is indebted to David Koos, the Company’s Chairman and Chief Executive Officer, in the amount of $151,286. These loans and any accrued interest are due and payable at the demand of Mr. Koos and bear simple interest at the rate of 15% per annum. As of June 30, 2015 Regen is indebted to David Koos, the Company’s Chairman and Chief Executive Officer, in the amount of $50. These loans and any accrued interest are due and payable at the demand of Mr. Koos and bear simple interest at the rate of 15% per annum. The Company utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 subleased to Regen by Entest BioMedical, Inc. on a month to month basis beginning October 1, 2014. The Chief Executive Officer of Entest Biomedical Inc. is David R. Koos who also serves as the Chief Executive Officer of the Company. The sublease is on a month to month basis and rent payable to Entest Biomedical, Inc. by Regen Biopharma Inc is equal to $5,000 per month, As of June 30, 2015 Entest Biomedical, Inc. is indebted to Regen in the amount of $12,051. $12,051 lent by Regen to Entest Biomedical, Inc . is due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum.

Notes Payable and Convertible N

Notes Payable and Convertible Notes Payable	9 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Notes Payable and Convertible Notes Payable	NOTE 7. NOTES PAYABLE AND CONVERTIBLE NOTES PAYABLE September 30, 2014 June 30, 2015 Bio Technology Partners Business Trust (Company) 35,000 14,000 Bio Technology Partners Business Trust (Regen) — 84,000 David R. Koos ( Company)( Note 6) 189,065 151,286 David R. Koos ( Regen)( Note 6) 30,168 50 The Sherman family Trust 125,000 2,500 Total $ 379,233 $ 251,836 Amounts due to the Biotechnology Partners Business Trust are due and payable at the demand of the holder and bear simple interest at a rate of 10% per annum. All loans to the Company and Regen made by David R. Koos are due and payable at the demand of Koos and bear simple interest at a rate of 15% per annum. All amounts due to the Sherman Family Trust bear no interest and are due and payable, in whole or in part, at the option of the holder. CONVERTIBLE NOTES PAYABLE JUNE 30, 2015 $50,000 Scott Levine $10,000 Mike and Ofie Weiner $18,400 Mike and Ofie Weiner $2,301 Bio Technology Partners Business Trust $300,000 Star City Capital, LLC $380,701 Total $300,000 due and payable to Starcity Capital LLC (“Note”) bears no interest, is payable on April 1, 2016 and permits conversion at the Holder’s option into common shares of the Company under the following terms and conditions: The Holder of the Note is entitled, at its option, at any time after 180 days after March 27, 2015 to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company's common stock (the "Common Stock") at a price ("Conversion Price") for each share of Common Stock equal to the greater of (iii) fifty five percent (55%) (the "Discount'') of the lowest closing bid price for the Company's common stock during the five (5) trading days immediately preceding a conversion date, as reported by Bloomberg (the "Closing Bid Price") ("Initial Conversion Price") or (iv) $0.0001. Upon : (i) a transfer of all or substantially all of the assets of the Company to any person in a single transaction or series of related transactions, (ii) a reclassification, capital reorganization or other change or exchange of outstanding shares of the Common Stock, or (iii) any consolidation or merger of the Company with or into another person or entity in which the Company is not the surviving entity (other than a merger which is effected solely to change the jurisdiction of incorporation of the Company and results in a reclassification, conversion or exchange of outstanding shares of Common Stock solely into shares of Common Stock) then, in each case, Holder may convert the unpaid principal amount of this Note into shares of Common Stock immediately prior to such event at the Conversion Price. other than as provided in (i), (ii) and(ii) above, the Holder shall not have the right to convert its debt into shares which, when added to such Holder’s other holdings in the Company stock, shall have caused such Holder to hold more than 9.99% of the Company’s outstanding common stock. The issuance of the Note amounted in a beneficial conversion feature of $300,000 which is amortized under the Interest Method over the life of the Note. The amount by which the instrument’s as converted value exceeds the principal amount as of June 30, 2015 is $245,454. $50,000 due and payable to Scott Levine bears simple interest at 12% per annum and is convertible into common shares of the company at $0.15 per share. The instrument became due and payable on November 14, 2009. No demand for payment has been made. $10,000 due and payable to Mike and Ofie Weiner bears simple interest at 12% per annum and is convertible into common shares of the company at $0.15 per share. The instrument became due and payable on March 3 , 2010. No demand for payment has been made. $18,400 due and payable to Mike and Ofie Weiner bears simple interest at 12% per annum and is convertible into common shares of the company at $0.15 per share. The instrument became due and payable on December 28, 2009. No demand for payment has been made. $2,301 due and payable to Bio Technology Partners Business Trust bears simple interest at 12% per annum and is convertible into common shares of the company at $0.15 per share. The instrument became due and payable on November 26, 2009. No demand for payment has been made. As of September 30, 2014 the unamortized discount on convertible notes outstanding is $0. As of June 30, 2015 the unamortized discount on convertible notes outstanding is $ 222,581. CONVERTIBLE NOTES ISSUED BY REGEN BIOPHARMA, INC. During the quarter ended March 31, 2015 Regen Biopharma, Inc. issued Convertible Notes ( “Notes”) with an aggregate face value of $882,686 . Consideration for these Notes consisted of: (a) $775,000 cash and (b) Satisfaction of $107,686 of existing indebtedness: Each Note becomes due and payable at the demand of the Lender at any time after one year subsequent to the issuance date and bears simple interest at 10% per annum payable quarterly at the demand of the Lender. All or part of the principal and accrued but unpaid interest is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price”) equivalent to a 65% discount to the lowest Trading Price (as defined below) for the Common Shares during the thirty (30) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the conversion date. “Trading Price” means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB”) as reported by a reliable reporting service (“Reporting Service”) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “œpink sheets” by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by Regen and the Lender. “Trading Day” shall mean any day on which the Common Shares are tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Shares are then being traded. “Trading Volume” shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by Regen relating to the Lender’s securities. Principal and interest may be prepaid in part or in full by Regen on not less than three Trading Days prior written notice to the Lender. Upon expiration of the six month holding specified in Rule 144(d) promulgated under the Securities Act of 1933, Regen , at the request of the Lender, shale remove sale restrictions on one sixth (1/6) of the shares that resulted from conversions made through the issuance of this Note , each month, for a period of six months, with all restrictions being removed by Regen Biopharma, Inc. by the expiration of the six month subsequent to expiration of the aforementioned Rule 144 holding period. If the Lender converts principal into Common Stock of Regen on or prior to 180 days from the issuance of the Note the Lender shall receive one share of Preferred Series “A” Stock of Regen Biopharma, Inc. for each share of Common Stock received through conversion. All Notes were fully converted during the quarter ended March 31, 2015. 31,539,262 common shares of Regen were issued to the Convertible Noteholders in satisfaction of the convertible indebtedness. 31,538,862 of Regen Biopharma, Inc.’s Series A Preferred shares were issued to Noteholders pursuant to the terms and conditions of the Notes. Regen Biopharma, Inc. analyzed the conversion feature of the Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging” and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in Regen Biopharma, Inc.’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. Regen Biopharma, Inc. values the embedded derivative using the Black-Scholes pricing model and an aggregate derivative liability of $2,368,685 was recognized by Regen Biopharma, Inc.. This liability was eliminated prior to the end of Regen Biopharma, Inc.’s second quarter as a result of the full conversion of all Notes prior to the end of Regen Biopharma, Inc.’s second quarter. During the quarter ended June 30, 2015 the Regen Biopharma, Inc. issued Convertible Notes ( “Notes”) with an aggregate face value of $90,000 . Consideration for these Notes consisted of $90,000. All or part of the principal and accrued but unpaid interest is convertible at any time at the demand of the Lender into the Common Shares of Regen at a price per share ( “Conversion Price“) equivalent the lower of (1) a 65% discount to the lowest Trading Price (as defined below) for the Common Shares during the thirty (30) Trading Day (as defined below) period ending on the latest complete Trading Day prior to the conversion date. “Trading Price“ means the closing bid price on the Over-the-Counter Bulletin Board, or applicable trading market (the “OTCQB“) as reported by a reliable reporting service (“Reporting Service“) designated by the Lender (i.e. Bloomberg) or, if the OTCQB is not the principal trading market for such security, the closing bid price of such security on the principal securities exchange or trading market where such security is listed or traded or, if no closing bid price of such security is available in any of the foregoing manners, the average of the closing bid prices of any market makers for such security that are listed in the “pink sheets“ by the National Quotation Bureau, Inc. If the Trading Price cannot be calculated for such security on such date in the manner provided above, the Trading Price shall be the fair market value as mutually determined by Regen and the Lender. “Trading Day“ shall mean any day on which the Common Shares are tradable for any period on the OTCQB, or on the principal securities exchange or other securities market on which the Common Shares are then being traded. “Trading Volume“ shall mean the number of shares traded on such Trading Day as reported by such Reporting Service. The Conversion Price shall be equitably adjusted for stock splits, stock dividends, rights offerings, combinations, recapitalization, reclassifications, extraordinary distributions and similar events by Regen relating to the Lender’s securities. Or (2) $0.03 per share Principal and interest may be prepaid in part or in full by Regen on not less than three Trading Days prior written notice to the Lender. Upon expiration of the six month holding specified in Rule 144(d) promulgated under the Securities Act of 1933, Regen , at the request of the Lender, shall remove sale restrictions on one sixth (1/6) of the shares that resulted from conversions made through the issuance of this Note , each month, for a period of six months, with all restrictions being removed by the Company by the expiration of the six month subsequent to expiration of the aforementioned Rule 144 holding period. If the Lender converts principal into Common Stock of Regen on or prior to 180 days from the issuance of the Note the Lender shall receive one share of Preferred Series A Stock of the Company for each share of Common Stock received through conversion. During the quarter ended June 30, 2015 the Regen issued 3,214,285 of its common shares in satisfaction of the abovementioned convertible notes and 3,214,285 shares of its Series A Preferred stock in accordance with the terms and conditions of abovementioned convertible notes. Regen Biopharma, Inc. analyzed the conversion feature of the Notes for derivative accounting consideration under ASC 815-15 “Derivatives and Hedging“ and determined that the embedded conversion feature should be classified as a liability due to their being no explicit limit to the number of shares to be delivered upon settlement of the above conversion features. ASC 815-15 requires that the conversion features are bifurcated and separately accounted for as an embedded derivative contained in Regen Biopharma, Inc.’s convertible debt. The embedded derivative is carried on the balance sheet at fair value. Any unrealized change in fair value, as determined at each measurement period, is recorded as a component of the income statement and the associated carrying amount on the balance sheet is adjusted by the change. Regen values the embedded derivative using the Black-Scholes pricing model and an aggregate derivative liability of $350,666 was recognized by the Company in connection with $90,000 of convertible notes payable issued during the quarter ended June 30, 2015. This liability was eliminated prior to the end of Regen’s third quarter as a result of the full conversion of these convertible noted prior to the end of Regen’s third quarter.

Stockholders Equity

Stockholders Equity	9 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Stockholders Equity	NOTE 8. STOCKHOLDERS' EQUITY The stockholders' equity section of the Company contains the following classes of capital stock as of June 30, 2015: Preferred stock, $0.0001 par value; 20,000,000 shares authorized: 2,063,821 Preferred Shares, par value $0.0001, issued and outstanding. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series B Preferred Stock owned by such holder times one (1). On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Preferred Stock shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation. 94,852 Series AA Preferred Shares, par value $0.0001, issued and outstanding. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times ten thousand (10,0000). On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Series AA Preferred Stock shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation. 40,000 Series AAA Preferred Shares, par value $0.0001, issued and outstanding. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series AA Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series AA Preferred Stock owned by such holder times one hundred thousand (100,0000). On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Series AA Preferred Stock shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation. 725,409 Series B Preferred Shares, Par Value $0.0001, issued and outstanding. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Series B Preferred Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Series B Preferred Stock owned by such holder times two (2). On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Series B Preferred Stock shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation. Non Voting Convertible Preferred Stock, $1.00 Par value, 200,000 shares authorized, 0 shares issued and outstanding Each Non Voting Convertible Preferred Stock shall convert at the option of the holder into shares of the corporation’s common stock at a conversion price equal to seventy percent (70%) of the lowest Closing Price for the five (5) trading days immediately preceding written receipt by the corporation of the holder’s intent to convert. “CLOSING PRICE" shall mean the closing bid price for the corporation’s common stock on the Principal Market on a Trading Day as reported by Bloomberg Finance L.P. “PRINCIPAL MARKET" shall mean the principal trading exchange or market for the corporation’s common stock. “TRADING DAY” shall mean a day on which the Principal Market shall be open for business. On any voluntary or involuntary liquidation, dissolution or winding up of the Corporation, the holders of the Non Voting Convertible Preferred shall receive, out of assets legally available for distribution to the Company's stockholders, a ratable share in the assets of the Corporation. Common stock, $ 0.0001 par value; 5,000,000,000 shares authorized: 4,232,931,245 shares issued and outstanding. With respect to each matter submitted to a vote of stockholders of the Corporation, each holder of Common Stock shall be entitled to cast that number of votes which is equivalent to the number of shares of Common Stock owned by such holder times one (1).

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 9. COMMITMENTS AND CONTINGENCIES On April 12, 2013 a complaint (Complaint) was filed in the U.S. District Court Southern District of the State of new York against the Company, the Company’s Chairman and Does 1-50 by Star city Capital, LLC (“Plaintiff”) alleging securities fraud, common law fraud, negligent misrepresentation, breach of fiduciary duties and breach of contract in connection with the issuance of. The Plaintiff is also request declaratory relief from the Court. The action arises from the issuance and subsequent cancellation of 103,030,303 of the company’s common shares in satisfaction of $17,000 of convertible indebtedness of the Company held by the Plaintiff. The Plaintiff alleges that a cancellation notice sent by them to the Company’s transfer agent was meant to instruct the Transfer Agent simply to cancel the physical certificate in order that an equivalent number of shares may be transferred via DWAC to the Plaintiff’s stockbroker for the benefit of the Plaintiff. DWAC is the acronym for Deposit/Withdrawal At Custodian. The DWAC transaction system run by The Depository Trust Company (a.k.a. DTC or CEDE & CO) permits brokers and custodial banks, the DTC participants, to request the movement of shares to or from the issuer’s transfer agent electronically. A DWAC results in the crediting or debiting of shares to or from DTC’s book-entry account on the records of the issuer maintained by the transfer agent. The Company believes that the cancellation notice sent by the Plaintiff clearly represents a cancellation of the conversion notice itself. The convertible indebtedness held by the Plaintiff was convertible at Holder’s demand into the common shares of the Company’s stock at a conversion price per share equal to 55% (the “Discount”) of the lowest closing bid price for the Company’s common stock during the 5 trading days immediately preceding a conversion date, as reported by Bloomberg (the “Closing Bid Price”); provided that if the closing bid price for the common stock on the date in which the conversion shares are deposited into Holder’s brokerage account and confirmation has been received that Holder may execute trades of the conversion shares ( Clearing Date) is lower than the Closing Bid Price, then the purchase price for the conversion shares would be adjusted such that the Discount shall be taken from the closing bid price on the Clearing Date, and the Company shall issue additional shares to Purchaser to reflect such adjusted Purchase Price(“Reset”). The Company and the Plaintiff had agreed on a limitation on conversion equal to 9.99% of the Company’s outstanding common stock. On February 2, 2015 Plaintiff and the Company entered into a Settlement Agreement and Mutual General Release to fully and finally resolve the aforementioned legal action pursuant to the following terms and conditions: (a) Within seven business days of the Company’s transfer agent’s receipt of an appropriate opinion of counsel, the Company shall deliver to Starcity or its designee or assignee (which designation or assignment shall be provided in writing) via DWAC, 103,030,303 of the common shares of the Company , it being the agreement of the parties that such issuance shall constitute full and complete satisfaction of $17,000 due to Starcity by the Company. (b) The Company shall deliver to Starcity a non interest bearing Convertible Note in the face amount of $300,000 (“Note”) due and payable April 1, 2016. The Holder of this Note is entitled, at its option, at any time after 180 days after the date that consideration of $52,500 is paid to the Company to convert all or any amount of the principal face amount of this Note then outstanding into shares of the Company's common stock (the "Common Stock") at a price ("Conversion Price") for each share of Common Stock equal to the greater of (i) fifty five percent (55%) (the "Discount'') of the lowest closing bid price for the Company's common stock during the five (5) trading days immediately preceding a conversion date, as reported by Bloomberg (the "Closing Bid Price") ("Initial Conversion Price") or (ii) $0.0001. Other than as provided in 5(p) of the Note ), the Holder shall not have the right to convert its debt into shares which, when added to such Holder’s other holdings in the Company stock, shall have caused such Holder to hold more than to hold more than 9.99% of the Company's outstanding common stock. Section 5(p) of the Note states that: Upon : (i) a transfer of all or substantially all of the assets of the Company to any person in a single transaction or series of related transactions, (ii) a reclassification, capital reorganization or other change or exchange of outstanding shares of the Common Stock, or (iii) any consolidation or merger of the Company with or into another person or entity in which the Company is not the surviving entity (other than a merger which is effected solely to change the jurisdiction of incorporation of the Company and results in a reclassification, conversion or exchange of outstanding shares of Common Stock solely into shares of Common Stock) then, in each case, Holder may convert the unpaid principal amount of this Note into shares of Common Stock immediately prior to such event at the Conversion Price. In the event that Starcity fails to fund the Note by making a payment of $52,500 to the Company on or before April 1, 2015, the Company’s obligations under this Note shall be terminated, cancelled and relinquished. On August 21, 2012 the Company entered into a settlement funding agreement with Princeton Research, Inc. and Jan Vandersande (collectively the “PRI Parties”) which obligates the Company to pay the PRI Parties $1,000 a month over thirty months. The Company utilizes approximately 2,300 square feet of office space at 4700 Spring Street, Suite 304, La Mesa California, 91941 subleased to Regen Biopharma, Inc. by Entest BioMedical, Inc. on a month to month basis beginning October 1, 2014. The Chief Executive Officer of Entest Biomedical Inc. is David R. Koos who also serves as the Chief Executive Officer of Regen and the Company. The sublease is on a month to month basis and rent payable to Entest Biomedical, Inc. by Regen Biopharma Inc is equal to $5,000 per month. On March 20, 2015 Regen Biopharma, Inc. agreed to sublease 199 square feet of laboratory space located at 5310 Eastgate Mall, San Diego, CA 92121 from Human BioMolecular Research Institute (“Sublease Agreement”). Pursuant to the terms of the Sublease Agreement Regen Biopharma, Inc. will pay rent of $400 per month to Human BioMolecular Research Institute (“HBRI”) . The term of the sublease shall be from March 9, 2015 to September 8, 2015 (a period of 6 months) and will automatically renew thereafter for the same 6 month term unless written notice is received by HBRI within 60 days prior to renewal. Regen Biopharma, Inc. terminated its sublease with Human BioMolecular Research Institute On March 20, 2015 Regen Biopharma, Inc entered into a Research Agreement with HBRI wherein HBRI agreed to provide a variety of professional, scientific and technical services for the proper conduct of research by Regen Biopharma, Inc. and also to make available certain research equipment to Regen Biopharma, Inc. The term of the agreement shall be from March 9, 2015 to September 8, 2015 (a period of 6 months) and will automatically renew thereafter for the same 6 month term unless written notice is received by HBRI within 60 days prior to renewal. As consideration Regen Biopharma, Inc shall pay a monthly fee of $2,700 to HBRI over the term of the agreement. Regen Biopharma, Inc. terminated the aforementioned agreement with Human BioMolecular Research Institute.

Investment Securities

Investment Securities	9 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Investment Securities	NOTE 10. INVESTMENT SECURITIES As of the quarter ending June 30, 2012 the Company reclassified 10,000,000 common shares of Entest (“Entest Shares”) as Securities Available for Sale from Securities Accounted for under the Equity Method. The Entest Shares are the Company’s sole Investment Securities as of June 30, 2015.

Stock Transactions

Stock Transactions	9 Months Ended
	Jun. 30, 2015
Notes to Financial Statements
Stock Transactions	NOTE 11. STOCK TRANSACTIONS Bio- Matrix Scientific Group, Inc.: On April 13, 2015 the company issued 200,000,000 Common Shares in satisfaction of $20,000 of indebtedness. Regen Biopharma, Inc.: Common Stock On April 14, 2015 Regen Biopharma, Inc. issued 1,428, 571 of its common shares in satisfaction of $40,000 of convertible indebtedness. On May 12, 2015 Regen Biopharma, Inc. issued 500,000 of its common shares in satisfaction of $15,000 of indebtedness. On May 18, 2015 Regen Biopharma, Inc. issued 500,000 of its common shares in satisfaction of $15,000 of indebtedness. On May 19, 2015 Regen Biopharma, Inc. issued 1,785,714 of its common shares in satisfaction of $50,000 of convertible indebtedness. Series A Preferred Stock On April 14, 2015 Regen Biopharma, Inc. issued 1,428, 571 of its shares of Series A Preferred Stock in accordance with the terms and conditions of a $40,000 face value convertible note issued by Regen Biopharma, Inc.. On May 19, 2015 Regen Biopharma, Inc. issued 200,000 of its shares of Series A Preferred Stock as consideration for services rendered by nonemployees. On May 19, 2015 Regen Biopharma, Inc. issued 1,785,714 of its shares of Series A Preferred Stock in accordance with the terms and conditions of a $50,000 face value convertible note issued by Regen Biopharma, Inc..

Subsequent Events

Subsequent Events	9 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	NOTE 12. SUBSEQUENT EVENTS On July 1, 2015 Regen Biopharma, Inc. issued 412,242 of its shares of common stock as consideration for services rendered by a nonemployee.

Organization and Summary of S19

Organization and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF ACCOUNTING	A. BASIS OF ACCOUNTING The financial statements have been prepared using the basis of accounting generally accepted in the United States of America. Under this basis of accounting, revenues are recorded as earned and expenses are recorded at the time liabilities are incurred. The Company has adopted a September 30 year-end.
PRINCIPLES OF CONSOLIDATION	B. PRINCIPLES OF CONSOLIDATION The consolidated financial statements include the accounts of Bio-Matrix Scientific Group, inc., a Delaware corporation, Bio Matrix Scientific Group, Inc, a Nevada corporation and a wholly owned subsidiary (“BMSG”), Regen BioPharma, Inc., a Nevada corporation and controlled subsidiary (Regen) and Entest BioMedical, Inc., (“Entest’), a Nevada corporation which was a majority owned subsidiary up to February 3, 2011.  Significant inter-company transactions have been eliminated.
USE OF ESTIMATES	C. USE OF ESTIMATES The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. All estimates are of a normal, recurring nature and are required for the fair presentation of the financial statements. Actual results could differ from those estimates.
CASH EQUIVALENTS	D. CASH EQUIVALENTS The Company considers all highly liquid investments with a maturity of three months or less when purchased to be cash equivalents.
PROPERTY AND EQUIPMENT	E. PROPERTY AND EQUIPMENT Property and equipment are recorded at cost. Maintenance and repairs are expensed in the year in which they are incurred. Expenditures that enhance the value of property and equipment are capitalized.
FAIR VALUE OF FINANCIAL INSTRUMENTS	F. FAIR VALUE OF FINANCIAL INSTRUMENTS Fair value is the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date.  A fair value hierarchy requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value: Level 1: Quoted prices in active markets for identical assets or liabilities Level 2: Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s financial instruments as of June 30, 2015 consisted of Securities Available for Sale consisting of 10,000,000 shares of Entest Biomedical, Inc and a Note Receivable from Entest Biomedical, Inc. for $12,051 . The fair value of Securities Available for sale as of June 30, 2015 were valued according to the Level 1 input. The carrying amount of the financial instruments is equal to the fair value as determined by the Company. The fair value of the Note Receivable was valued according to Level 3 input.
INCOME TAXES	G. INCOME TAXES The Company accounts for income taxes using the liability method prescribed by ASC 740, “Income Taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company applied the provisions of ASC 740-10-50, “Accounting For Uncertainty In Income Taxes, which provides clarification related to the process associated with accounting for uncertain tax positions recognized in our financial statements. Audit periods remain open for review until the statute of limitations has passed. The completion of review or the expiration of the statute of limitations for a given audit period could result in an adjustment to the Company’s liability for income taxes. Any such adjustment could be material to the Company’s results of operations for any given quarterly or annual period based, in part, upon the results of operations for the given period. As of June 30, 2015 the Company had no uncertain tax positions, and will continue to evaluate for uncertain positions in the future. The Company generated a deferred tax credit through net operating loss carry forward.  However, a valuation allowance of 100% has been established. Interest and penalties on tax deficiencies recognized in accordance with ACS accounting standards are classified as income taxes in accordance with ASC Topic 740-10-50-19.
BASIC EARNINGS (LOSS) PER SHARE	H. The Financial Accounting Standards Board (FASB) issued Accounting Standards Codification (ASC) 260, "Earnings Per Share", which specifies the computation, presentation and disclosure requirements for earnings (loss) per share for entities with publicly held common stock. ASC 260 requires the presentation of basic earnings (loss) per share and diluted earnings (loss) per share. The Company has adopted the provisions of ASC 260 effective from inception. Basic net loss per share amounts is computed by dividing the net income by the weighted average number of common shares outstanding. All options and convertible debt outstanding has an anti-dilutive effect on the EPS, therefore Diluted Earnings per Share are the same as basic earnings per share.
ADVERTISING	I. ADVERTISING Costs associated with advertising are charged to expense as incurred. Advertising expenses were $0 and $0 for the quarter ended June 30, 2015 and the year ended September 30, 2014 respectively.

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Deferred tax assets	Deferred tax assets: Net operating tax carry forwards $ 10,412,444 Other -0- Gross deferred tax assets 10,412, 444 Valuation allowance (10,412,444 ) Net deferred tax assets $ -0-

Notes Payable and Convertible21

Notes Payable and Convertible Notes Payable (Tables)	9 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Notes Payable	September 30, 2014 June 30, 2015 Bio Technology Partners Business Trust (Company) 35,000 14,000 Bio Technology Partners Business Trust (Regen) — 84,000 David R. Koos ( Company)( Note 6) 189,065 151,286 David R. Koos ( Regen)( Note 6) 30,168 50 The Sherman family Trust 125,000 2,500 Total $ 379,233 $ 251,836
Convertible Notes Payable	$50,000 Scott Levine $10,000 Mike and Ofie Weiner $18,400 Mike and Ofie Weiner $2,301 Bio Technology Partners Business Trust $300,000 Star City Capital, LLC $380,701 Total

Organization and Summary of S22

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Feb. 03, 2011	Jul. 03, 2006
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Acquired share capital of Bio-Maxtrix Scientific Gruop, Inc.				100.00%
Consideration of shares of common stock of the Company				10,000,000
Cancelation of shares of the Company owned and held by John Lauring				10,000,000
Percent of voting capital stock of the Company held by former stockholder of BMSG				80.00%
Owned subsidiary, Regen BioPharma, Inc.			96.00%
Shares of Entest BioMedical, Inc. for Securities Available for Sale	10,000,000
Note receivable from Entest BioMedical	$ 12,051
Advertising expenses	$ 0	$ 0

Going Concern (Details Narrativ

Going Concern (Details Narrative) - USD ($)	3 Months Ended		119 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Non-cash gain upon deconsolidation ofEntest Biomedical, Inc.			$ 41,645,688
Net Losses			30,586,221
Equity in Net Losses of Entest Biomedical, Inc.			$ 663,649
Proceeds from issuance of convertible debt	$ 90,000	$ 775,000

Income Taxes - Deferred tax ass

Income Taxes - Deferred tax assets (Details)	Jun. 30, 2015USD ($)
Deferred tax assets:
Net operating tax carry forwards	$ 10,412,444
Other	0
Gross deferred tax assets	10,412,444
Valuation allowance	(10,412,444)
Net deferred tax assets	$ 0

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - Jun. 30, 2015 - USD ($)	Total
Income Tax Disclosure [Abstract]
Deferred tax asset	$ 10,412,444
Net operating loss carry forwards	30,624,837
Amount of NOL acuired in reverse aquisition fo BMSG	38,616
Amount of NOL attributable to Bio-Matrix Scientific Group, Inc.	$ 30,586,221
Federal Corporate income tax Rate	34.00%

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - Jun. 30, 2015 - USD ($)	Total
Related Party Transactions [Abstract]
Amount due to CEO	$ 151,286
Amount due to CEO from subsidiary	$ 50
Simple interest rate on notes due to CEO	15.00%
Monthly lease revenue from Regen Biopharma to Entest Biomedical	$ 5,000
Entest Biomedical indebtedness to Regen	$ 12,051
Interest rate on note receivable from Entest	10.00%

Notes Payable and Convertible27

Notes Payable and Convertible Notes Payable - Notes Payable (Details) - USD ($)	Jun. 30, 2015	Sep. 30, 2014
Debt Disclosure [Abstract]
Bio Technology Partners Business Trust (Company)	$ 14,000	$ 35,000
Bio Technology Partners Business Trust (Regen)	84,000
David R. Koos ( Company)( Note 6)	151,286	$ 189,065
David R. Koos ( Regen)( Note 6)	50	30,168
The Sherman family Trust	2,500	125,000
Total	$ 251,836	$ 379,233

Notes Payable and Convertible28

Notes Payable and Convertible Notes Payable - Convertible Notes Payable (Details)	Jun. 30, 2015USD ($)
Debt Disclosure [Abstract]
Scott Levine	$ 50,000
Mike and Ofie Weiner	10,000
Mike and Ofie Weiner	18,400
Bio Technology Partners Business Trust	2,301
Star City Capital, LLC	300,000
Total	$ 380,701

Notes Payable and Convertible29

Notes Payable and Convertible Notes Payable (Details Narrative) - USD ($)	3 Months Ended
	Jun. 30, 2015	Mar. 31, 2015	Sep. 30, 2014
Debt Disclosure [Abstract]
Convertible notes, annual interest rate	12.00%
Convertible notes, conversion price	$ .15
Unamortized discount on convertible notes outstanding	$ 222,581		$ 0
Convertible notes issued by Regen Biopharma		$ 882,686
Cash consideration for issued notes by Regen Biopharma	90,000	775,000
Satisfaction of existing indebtedness		$ 107,686
Common shares issued upon conversion of notes payable		31,539,262
Series A preferred shares issued upon conversion of notes payable		31,538,862
Derivative liability	350,666	$ 2,368,685
Convertible notes issued	$ 90,000
Common stock issued in satisfaction of convertible debt	3,214,285

Stockholders Equity (Details Na

Stockholders Equity (Details Narrative) - $ / shares	Jun. 30, 2015	Sep. 30, 2014
Preferred stock; par value	$ 0.0001	$ 0.0001
Preferred stock; shares authorized	20,000,000	20,000,000
Preferred stock; shares issued	2,063,821	2,063,821
Preferred stock; shares outstanding	2,063,821	2,063,821
Common stock; par value	$ 0.0001	$ 0.0001
Common Stock; shares authorized	5,000,000,000	5,000,000,000
Common stock; shares issued	4,232,931,345	3,079,900,942
Common stock; shares outstanding	4,232,931,345	3,079,900,942
Series AA
Preferred stock; par value	$ 0.0001	$ 0.0001
Preferred stock; shares authorized	100,000	100,000
Preferred stock; shares issued	94,852	94,852
Preferred stock; shares outstanding	94,852	94,852
Series AAA
Preferred stock; par value	$ 0.0001	$ 0.0001
Preferred stock; shares authorized	1,000,000	1,000,000
Preferred stock; shares issued	40,000	40,000
Preferred stock; shares outstanding	40,000	40,000
Series B
Preferred stock; par value	$ 0.0001	$ 0.0001
Preferred stock; shares authorized	2,000,000	2,000,000
Preferred stock; shares issued	725,409	725,409
Preferred stock; shares outstanding	725,409	725,409
Non-Voting
Preferred stock; par value	$ 1	$ 1
Preferred stock; shares authorized	200,000	200,000
Preferred stock; shares issued	0	0
Preferred stock; shares outstanding	0	0

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)	1 Months Ended
	Aug. 31, 2012	Mar. 20, 2015	Feb. 02, 2015	Apr. 12, 2013
Commitments and Contingencies Disclosure [Abstract]
Cancellation of company common shares held by Plaintiff				103,030,303
Satisfaction of convertible indebtedness held by Plaintiff				$ 17,000
Limitation on conversion of outstanding common stock				9.99%
Convertible Note to plaintiff, payable April 1, 2016			$ 300,000
Payment for consideration of note conversion			$ 52,500
Conversion discount rate			55.00%
Settlement with PRI Parties, payment per month	$ 1,000
Regen Biopharma monthly sublease fee to HBRI		$ 400
Regen Biopharma monthly research agreement fee		$ 2,700

Investment Securities (Details

Investment Securities (Details Narrative)	Jun. 30, 2015USD ($)
Accounting Policies [Abstract]
Common shares of Entest classified as Investment Securities	$ 10,000,000

Stock Transactions (Details Nar

Stock Transactions (Details Narrative) - USD ($)	May. 19, 2015	May. 18, 2015	May. 12, 2015	Apr. 14, 2015	Apr. 13, 2015
Notes to Financial Statements
Common stock issued in satisfaction of convertible debt	1,785,714	500,000	500,000	1,428,571	200,000,000
Amount of convertible debt satisfied	$ 50,000	$ 15,000	$ 15,000	$ 40,000	$ 20,000
Regen Biopharma Series A preferred stock issued for convertible debt	1,785,714			1,428,571
Amount of debt satisfied	$ 50,000			$ 40,000
Regen Biopharma Series A stock issued for consulting services	200,000

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	Jul. 01, 2015shares
Subsequent Events [Abstract]
Common stock issued for services	412,242